|
|
|
| Expression and Significance of Mismatch Repair Protein in Malignant Epithelial Tumors in Different Parts of the Large Intestine |
| DUAN Yongdong, DAI Junli |
| Chengde Central Hospital, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To investigate the expression of mismatch repair protein (MMR) in colorectal cancer tissues in different parts of the large intestine and the significance of MMR expression in colorectal cancer. Methods: The expression and significance of mismatch repair proteins (msh1, MSH2, MSH6, and PMS2) in colorectal cancer tissues were analyzed by immunohistochemical method (SP method), and the expression significance of MMR protein in different parts of colorectal cancer was analyzed. Deletion of one or more of msh1, MSH2, MSH6 and PMS2 proteins was determined as mismatch repair gene defect (dmmr), and all expression levels were determined as mismatch repair gene integrity (PMMR). Results: In 168 cases of colorectal cancer, there were 141 cases (83.93%) of PMMR, 27 cases (16.07%) of dmmr, 56 cases (71.79%) of MMR protein expression loss group (dmmr) and 22 cases (28.21%) of MMR protein non deletion group (PMMR) in 78 cases of normal colorectal mucosa adjacent to carcinoma (P<0.05). In 47 cases of right colon cancer, there were 19 cases (40.42%) of dmmr, 5 cases (5.43%) of left colon cancer, 3 cases (10.34%) of 29 cases of rectal cancer. Furthermore, there was a certain relationship between dmmr and clinicopathological features of colorectal cancer. The dmmr in the group with lymph node metastasis and invasion into the muscular layer was significantly lower than that in the group without lymph node metastasis and the group with invasion of muscle layer (P<0.05). Conclusion: The expression of mismatch repair protein in colorectal cancer is higher than that in normal intestinal mucosa, and the expression of mismatch repair protein is different in different parts of colorectal cancer. Different status of mismatch repair protein is related to the progress of colorectal cancer, and suggests that the prognosis of colorectal cancer with mismatch repair protein deficiency may be better.
|
|
|
|
|
|
[1] Stewart BW, Wild CP.World Cancer Report 2014[M]. Lyon:International agency for research on cancer, 2014.392~402.
[2] 谢晓丹.错配修复蛋白四项和p53蛋白表达与结直肠癌的临床病理关系及其相关性分析[J].医药前沿, 2020, 10(2):131~132.
[3] Leskela S , Romero I , Cristobal E, et al.Mismatch repair deficiency in ovarian carcinoma: frequency, causes and consequences[J].Am Surg Pathol 2020, 44 (5): 649~656.
[4] 郭源, 张龙, 张舜, 等.结直肠癌错配修复蛋白表达及微卫星不稳定与TNM分期的相关性[J].肿瘤研究与临床, 2019, 31(6):376~380.
[5] 李宇阳, 丁祺, 董丽儒, 等.错配修复蛋白MLH1 MSH2 MSH6 及 PMS2在结直肠癌中的表达及其临床意义[J].河北医学, 2019, 25(4):536~539.
[6] Ju JY , Dibbern ME , Mahadevan MS, et al. Mismatch repair protein deficiency/microsatellite instability is rare in cholangiocarcinomas and associated with distinctive morphologies[J].Am Clin Pathol 2020, 153 (5): 598~604.
[7] 王超, 高志冬, 姜可伟, 等.结肠癌组织中错配修复蛋白表达及其对患者预后的影响[J].中华普通外科杂志, 2019, 34(4):349~352.
[8] Neumann J , Heinemann V , Engel J , et al.The prognostic impact of CDχ2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer[J].Virchows Arch, 2018, 473 (2): 199~207.
[9] Leicher LW , Lammertink MHA , Offerman SR, et al. Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice[J].Scand Gastroenterol 2018, 53 (5): 632~636. |
|
|
|
2020, Vol. 26 
